These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8172444)

  • 1. HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
    Jacobs MB
    Ann Intern Med; 1994 Jun; 120(11):970. PubMed ID: 8172444
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.
    Ehrenberg BL; Lamon-Fava S; Corbett KE; McNamara JR; Dallal GE; Schaefer EJ
    Sleep; 1999 Feb; 22(1):117-21. PubMed ID: 9989373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin and peripheral neuropathy.
    Ahmad S
    Am Heart J; 1995 Dec; 130(6):1321. PubMed ID: 7484806
    [No Abstract]   [Full Text] [Related]  

  • 5. Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
    Med Lett Drugs Ther; 1992 Jun; 34(872):57-8. PubMed ID: 1593973
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
    Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR
    Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
    Golay A; Lehmann T; James R; Pometta D
    Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of hypotension with lovastatin and pravastatin.
    Kostis JB; Wilson AC
    Lancet; 1991 Nov; 338(8778):1339. PubMed ID: 1682723
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
    Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
    Tobert JA
    Am J Cardiol; 1995 Apr; 75(12):862. PubMed ID: 7717303
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 16. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men.
    Strandberg TE; Räikkönen K; Partinen M; Pihl S; Vanhanen H; Miettinen TA
    Biol Psychiatry; 1994 Apr; 35(8):575-7. PubMed ID: 8038303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.